{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:13:19Z","timestamp":1789096399244,"version":"build-2803163510"},"reference-count":66,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013318","name":"Shanxi Provincial Department of Science and Technology","doi-asserted-by":"crossref","award":["202403021222401"],"award-info":[{"award-number":["202403021222401"]}],"id":[{"id":"10.13039\/501100013318","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease caused by JC virus reactivation in immunocompromised patients. With the increasing use of immunosuppressants and biologics, PML reporting in non-HIV populations is rising. This study aimed to evaluate drug-associated PML reporting signals using real-world pharmacovigilance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We analyzed FAERS database from 2004Q1 to 2024Q4. We identified PML reports via MedDRA Terms and manual validation. Four algorithms\n                      <jats:bold>(ROR, PRR, BCPNN, MGPS)<\/jats:bold>\n                      were jointly applied, with drugs showing signals across all four defined as high-risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>7,244 PML reports involving 298 drugs were identified; 72 drugs showed consistent signals, predominantly immunomodulators (e.g., natalizumab, rituximab), antineoplastics, and biologics. High-risk indications included multiple sclerosis, lymphoma, autoimmune diseases, and organ transplantation. PML reporting increased substantially in non-HIV populations. Time-to -reporting varied widely (49\u20131343days). Over one-third of reports were associated with life-threatening outcomes or death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis identified 72 drugs with consistent PML reporting signals. However, these findings represent statistical associations in spontaneous reports, not causal relationships or true incidence rates. Inherent limitations\u2014including underreporting, incomplete medication histories, and lack of exposure denominators\u2014require cautious interpretation. Prospective validation studies are essential to establish causality and quantify absolute risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0341855","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:22:15Z","timestamp":1770142935000},"page":"e0341855","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database"],"prefix":"10.1371","volume":"21","author":[{"given":"Hailong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-0950","authenticated-orcid":true,"given":"Lijuan","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"4","key":"pone.0341855.ref001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"CS Tan","year":"2010","journal-title":"Lancet Neurol"},{"issue":"16","key":"pone.0341855.ref002","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1212\/WNL.0000000000207622","article-title":"Progressive multifocal leukoencephalopathy: pathogenesis, diagnostic tools, and potential biomarkers of response to therapy","volume":"101","author":"F Schweitzer","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"pone.0341855.ref003","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-107-1-78","article-title":"Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases","volume":"107","author":"JR Berger","year":"1987","journal-title":"Ann Intern Med"},{"issue":"8","key":"pone.0341855.ref004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.17116\/jnevro202412408139","article-title":"Progressive multifocal leukoencephalopathy in HIV-positive individuals","volume":"124","author":"DO Tarasov","year":"2024","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"1","key":"pone.0341855.ref005","first-page":"24","article-title":"Progressive multifocal leukoencephalopathy - epidemiology, immune response, clinical differences, treatment","volume":"68","author":"S Snopkov\u00e1","year":"2019","journal-title":"Epidemiol Mikrobiol Imunol"},{"issue":"10","key":"pone.0341855.ref006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1473-3099(09)70226-9","article-title":"Progressive multifocal leukoencephalopathy in HIV-1 infection","volume":"9","author":"P Cinque","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pone.0341855.ref007","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s13365-014-0289-8","article-title":"Progressive multifocal leukoencephalopathy therapy","volume":"21","author":"DB Clifford","year":"2015","journal-title":"J Neurovirol"},{"issue":"1","key":"pone.0341855.ref008","doi-asserted-by":"crossref","first-page":"14291","DOI":"10.1038\/s41598-023-41147-9","article-title":"Long-term prognosis and overall mortality in patients with progressive multifocal leukoencephalopathy","volume":"13","author":"J Kim","year":"2023","journal-title":"Sci Rep"},{"key":"pone.0341855.ref009","first-page":"109","article-title":"Progressive multifocal leukoencephalopathy: current insights","volume":"9","author":"M Kartau","year":"2019","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"10","key":"pone.0341855.ref010","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00415-016-8217-x","article-title":"Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases","volume":"263","author":"RPPWM Maas","year":"2016","journal-title":"J Neurol"},{"issue":"6","key":"pone.0341855.ref011","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2077","article-title":"Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab","volume":"29","author":"D Focosi","year":"2019","journal-title":"Rev Med Virol"},{"issue":"1","key":"pone.0341855.ref012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"I Cortese","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"pone.0341855.ref013","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ana.26198","article-title":"Advances in treatment of progressive multifocal leukoencephalopathy","volume":"90","author":"R Bernard-Valnet","year":"2021","journal-title":"Ann Neurol"},{"issue":"4","key":"pone.0341855.ref014","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s13311-017-0570-7","article-title":"Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies","volume":"14","author":"EML Williamson","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"9","key":"pone.0341855.ref015","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2024-260624","article-title":"Progressive multifocal leukoencephalopathy in systemic lupus erythematosus treated with pembrolizumab","volume":"17","author":"M \u00d8rum","year":"2024","journal-title":"BMJ Case Rep"},{"key":"pone.0341855.ref016","doi-asserted-by":"crossref","first-page":"106163","DOI":"10.1016\/j.msard.2024.106163","article-title":"Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: a large case series","volume":"92","author":"D Croteau","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"pone.0341855.ref017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200476","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy after natalizumab extended interval dosing therapy in Japan","volume":"12","author":"K Takahashi","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"pone.0341855.ref018","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.885","article-title":"Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting","volume":"12","author":"JS Almenoff","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"pone.0341855.ref019","first-page":"143","article-title":"Potential use of data-mining algorithms for the detection of \u201csurprise\u201d adverse drug reactions","volume":"30","author":"M Hauben","year":"2007","journal-title":"Drug Saf"},{"issue":"7","key":"pone.0341855.ref020","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"pone.0341855.ref021","author":"U.S. Food and Drug Administration"},{"issue":"1","key":"pone.0341855.ref022","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40360-024-00821-y","article-title":"A real-world disproportionality analysis of the US Food and Drug Administration (FDA) adverse event reporting system (FAERS) events for Durvalumab","volume":"25","author":"T Zou","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"issue":"14","key":"pone.0341855.ref023","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/sim.1157","article-title":"On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios","volume":"21","author":"PGM van der Heijden","year":"2002","journal-title":"Stat Med"},{"key":"pone.0341855.ref024","doi-asserted-by":"crossref","first-page":"1420478","DOI":"10.3389\/fphar.2024.1420478","article-title":"Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023","volume":"15","author":"J Lin","year":"2024","journal-title":"Front Pharmacol"},{"issue":"6","key":"pone.0341855.ref025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"13","key":"pone.0341855.ref026","article-title":"Adverse events associated with eteplirsen: a disproportionality analysis using the 2016-2023 FAERS data","volume":"10","author":"Z Dai","year":"2024","journal-title":"Heliyon"},{"issue":"8","key":"pone.0341855.ref027","first-page":"138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"G Park","year":"2020","journal-title":"Life (Basel)"},{"key":"pone.0341855.ref028","doi-asserted-by":"crossref","DOI":"10.5772\/50095","article-title":"Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS)","author":"E Poluzzi","year":"2012","journal-title":"Data Mining Applications in Engineering and Medicine"},{"issue":"11","key":"pone.0341855.ref029","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00147-004-0779-3","article-title":"Progressive multifocal leukoencephalopathy in transplant recipients","volume":"17","author":"D Shitrit","year":"2005","journal-title":"Transpl Int"},{"issue":"9","key":"pone.0341855.ref030","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"ES Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"pone.0341855.ref031","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"F Zaheer","year":"2012","journal-title":"Ther Adv Drug Saf"},{"issue":"8","key":"pone.0341855.ref032","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system","volume":"15","author":"DW Raisch","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0341855.ref033","doi-asserted-by":"crossref","first-page":"989032","DOI":"10.3389\/fphar.2022.989032","article-title":"Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system","volume":"13","author":"T Jiang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"pone.0341855.ref034","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2023.12.037","article-title":"Xist ribonucleoproteins promote female sex-biased autoimmunity","volume":"187","author":"DR Dou","year":"2024","journal-title":"Cell"},{"key":"pone.0341855.ref035","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fendo.2019.00265","article-title":"Autoimmune disease in women: endocrine transition and risk across the lifespan","volume":"10","author":"MK Desai","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"pone.0341855.ref036","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awac237","article-title":"Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions","volume":"146","author":"M Joly","year":"2023","journal-title":"Brain"},{"issue":"8","key":"pone.0341855.ref037","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1352458518786075","article-title":"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"25","author":"Y Oshima","year":"2019","journal-title":"Mult Scler"},{"key":"pone.0341855.ref038","doi-asserted-by":"crossref","first-page":"1334468","DOI":"10.3389\/fdsfr.2024.1334468","article-title":"Progressive multifocal leukoencephalopathy reports in rheumatoid arthritis concerning different treatment patterns-an exploratory assessment using the food and drug administration adverse event reporting system","volume":"4","author":"T Honma","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"pone.0341855.ref039","doi-asserted-by":"crossref","first-page":"120459","DOI":"10.1016\/j.jns.2022.120459","article-title":"Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: a review","volume":"443","author":"K Sharma","year":"2022","journal-title":"J Neurol Sci"},{"issue":"2","key":"pone.0341855.ref040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2008.07.006","article-title":"Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?","volume":"8","author":"ES Molloy","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"1","key":"pone.0341855.ref041","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/NRL.0b013e31827c6c3d","article-title":"Progressive multifocal leukoencephalopathy as the first manifestation of occult sarcoidosis: case report and review of the literature","volume":"19","author":"MJ Davis","year":"2013","journal-title":"Neurologist"},{"issue":"9","key":"pone.0341855.ref042","first-page":"667","article-title":"Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus: Could CD4+ lymphopenia be the main risk factor?","volume":"35","author":"L Casado","year":"2020","journal-title":"Neurologia (Engl Ed)"},{"issue":"5","key":"pone.0341855.ref043","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/acn3.190","article-title":"CD4 cell response to interval therapy with natalizumab","volume":"2","author":"R Berkovich","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"pone.0341855.ref044","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13075-016-1152-5","article-title":"Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","volume":"18","author":"M Lavielle","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"pone.0341855.ref045","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00296-015-3295-0","article-title":"Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab","volume":"35","author":"S Piantoni","year":"2015","journal-title":"Rheumatol Int"},{"issue":"11","key":"pone.0341855.ref046","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.3109\/10428194.2015.1026818","article-title":"Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma","volume":"56","author":"T Yutaka","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"pone.0341855.ref047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018506","article-title":"Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders","volume":"6","author":"A Haghikia","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"pone.0341855.ref048","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000177","article-title":"Low frequencies of central memory CD4 T cells in progressive multifocal leukoencephalopathy","volume":"2","author":"E Dubois","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"pone.0341855.ref049","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"DW Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"13","key":"pone.0341855.ref050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"FJ Jr Palella","year":"1998","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0341855.ref051","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jac\/dki444","article-title":"Immune reconstitution inflammatory syndrome: more answers, more questions","volume":"57","author":"SA Shelburne","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"pone.0341855.ref052","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/WCO.0b013e328346be57","article-title":"Immune reconstitution inflammatory syndrome and the central nervous system","volume":"24","author":"T Johnson","year":"2011","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"pone.0341855.ref053","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/QCO.0b013e328352b664","article-title":"Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients","volume":"25","author":"G Martin-Blondel","year":"2012","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"pone.0341855.ref054","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1212\/WNL.0b013e31822e55e7","article-title":"Immune reconstitution inflammatory syndrome in natalizumab-associated PML","volume":"77","author":"IL Tan","year":"2011","journal-title":"Neurology"},{"issue":"17","key":"pone.0341855.ref055","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/01.wnl.0000343510.08643.74","article-title":"PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids","volume":"72","author":"K Tan","year":"2009","journal-title":"Neurology"},{"issue":"10","key":"pone.0341855.ref056","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.3390\/ijms24108580","article-title":"An elusive target: inhibitors of JC polyomavirus infection and their development as therapeutics for the treatment of progressive multifocal leukoencephalopathy","volume":"24","author":"J Kaiserman","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"pone.0341855.ref057","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10875-024-01698-6","article-title":"Treatment of progressive multifocal leukoencephalopathy with IL-2 and mirtazapine","volume":"44","author":"L Schweitzer","year":"2024","journal-title":"J Clin Immunol"},{"issue":"1","key":"pone.0341855.ref058","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13365-023-01114-6","article-title":"Successful treatment of HIV-associated progressive multifocal leukoencephalopathy (PML) with mirtazapine, mefloquine, and IVIG combination therapy: a case report","volume":"29","author":"B Cifci","year":"2023","journal-title":"J Neurovirol"},{"issue":"5","key":"pone.0341855.ref059","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/AAC.01614-08","article-title":"Identification and characterization of mefloquine efficacy against JC virus in vitro","volume":"53","author":"M Brickelmaier","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0341855.ref060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13365-013-0173-y","article-title":"A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes","volume":"19","author":"DB Clifford","year":"2013","journal-title":"J Neurovirol"},{"issue":"2","key":"pone.0341855.ref061","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","article-title":"Defining \u201csignal\u201d and its subtypes in pharmacovigilance based on a systematic review of previous definitions","volume":"32","author":"M Hauben","year":"2009","journal-title":"Drug Saf"},{"issue":"20","key":"pone.0341855.ref062","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000005529","article-title":"Progressive multifocal leukoencephalopathy after fingolimod treatment","volume":"90","author":"JR Berger","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"pone.0341855.ref063","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40263-015-0226-2","article-title":"Infection risk in patients on multiple sclerosis therapeutics","volume":"29","author":"EM Williamson","year":"2015","journal-title":"CNS Drugs"},{"issue":"12","key":"pone.0341855.ref064","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"N Schwab","year":"2017","journal-title":"Neurology"},{"issue":"8","key":"pone.0341855.ref065","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14740338.2024.2387316","article-title":"Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects","volume":"24","author":"L Jin","year":"2025","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"pone.0341855.ref066","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1038\/s41598-025-89272-x","article-title":"Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database","volume":"15","author":"B-K Zhu","year":"2025","journal-title":"Sci Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:22:26Z","timestamp":1770142946000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341855"}},"subtitle":[],"editor":[{"given":"Mehmet","family":"Baysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":66,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341855","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}